Detection of Protein Biomarker Using a Blood Glucose Meter

Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1256)

Abstract

mHeath technologies are recognized to play important roles in the future of personal care and medicine. However, their full potentials have not been reached, as most of current technologies are restricted to monitoring physical and behavioral parameters, such as body temperature, heart rate, blood pressure, and physical movement, while direct monitoring of biomarkers in body fluids can provide much more accurate and useful information for medical diagnostics. A major barrier to realizing the full potential of mHealth is the high costs and long cycles of developing mHealth devices capable of monitoring biomarkers in body fluids. To lower the costs and shorten the developmental cycle, we have demonstrated the leveraging of the most successful portable medical monitoring device on the market, the blood glucose meter (BGM), with FDA-approved smartphone technologies that allow for wireless transmission and remote monitoring of a wide range of non-glucose targets. In this protocol, an aptamer-based assay for quantification of interferon-γ (IFN-γ) using an off-the-shelf BGM is described. In this assay, an aptamer-based target recognition system is employed. When IFN-γ binds to the aptamer, it triggers the release of a reporter enzyme, invertase, which can catalyze the conversion of sucrose (not detected by BGM) to glucose. The glucose being produced is then detected using a BGM. The system mimics a competitive enzyme-linked immunosorbent assay (ELISA), where the traditional immunoassay is replaced by an aptamer binding assay; the reporter protein is replaced by invertase, and finally the optical or fluorescence detector is replaced with widely available BGMs.

Key words

Blood glucose meter (BGM) Aptamer Biosensor Point-of-care diagnostic Electrochemical sensor 

Notes

Acknowledgements

This material is based upon work supported by the US National Institutes of Health (RDA035524A and RDK100213A and ES16865) and National Science Foundation (IIP-1330934).

References

  1. 1.
    mHealth G. Device Listing (2012) A global list of commercially available devices in the healthcare sector, updated fortnightly 2012. http://www.gsma.com/connectedliving/wp-content/uploads/2012/04/22-November12_MobileHealth_Device_Listing.pdf
  2. 2.
    Chin CD, Cheung YK, Laksanasopin T, Modena MM, Chin SY, Sridhara AA et al (2013) Mobile device for disease diagnosis and data tracking in resource-limited settings. Clin Chem 59(4):629–640CrossRefGoogle Scholar
  3. 3.
    iBG STAR, 510(k) Substantial Equivalence Determination Decision Summary (510(k) number: k103544)Google Scholar
  4. 4.
    iBGSTAR (2011) iBGStar® blood glucose meter. Sanofi (updated 2011; cited 2011 Dec 1) http://www.bgstar.com/web/ibgstar
  5. 5.
    Telcare (2013) Telcare (updated 2013; cited 2013 09/09) https://www.telcare.com/
  6. 6.
    Hones J, Muller P, Surridge N (2008) The technology behind glucose meters: test strips. Diabetes Technol Ther 10:S10–S26CrossRefGoogle Scholar
  7. 7.
    Xiang Y, Lu Y (2011) Using personal glucose meters and functional DNA sensors to quantify a variety of analytical targets. Nature Chem 3(9):697–703, PMCID: 3299819CrossRefGoogle Scholar
  8. 8.
    Xiang Y, Lu Y (2012) Using commercially available personal glucose meters for portable quantification of DNA. Anal Chem 84(4):1975–1980, PMCID: 3302979CrossRefGoogle Scholar
  9. 9.
    Xiang Y, Lu Y (2012) Portable and quantitative detection of protein biomarkers and small molecular toxins using antibodies and ubiquitous personal glucose meters. Anal Chem 84(9):4174–4178, PMCID: 3341531CrossRefGoogle Scholar
  10. 10.
    Nie Z, Deiss F, Liu X, Akbulut O, Whitesides GM (2010) Integration of paper-based microfluidic devices with commercial electrochemical readers. Lab Chip 10(22):3163–3169, PMCID: 3060706CrossRefGoogle Scholar
  11. 11.
    Su J, Xu J, Chen Y, Xiang Y, Yuan R, Chai Y (2012) Personal glucose sensor for point-of-care early cancer diagnosis. Chem Commun (Camb) 48(55):6909–6911CrossRefGoogle Scholar
  12. 12.
    Yan L, Zhu Z, Zou Y, Huang Y, Liu D, Jia S et al (2013) Target-responsive “sweet” hydrogel with glucometer readout for portable and quantitative detection of non-glucose targets. J Am Chem Soc 135(10):3748–3751CrossRefGoogle Scholar
  13. 13.
    Boehm U, Klamp T, Groot M, Howard JC (1997) Cellular responses to interferon-gamma. Annu Rev Immunol 15:749–795CrossRefGoogle Scholar
  14. 14.
    Liu Y, Kwa T, Revzin A (2012) Simultaneous detection of cell-secreted TNF-alpha and IFN-gamma using micropatterned aptamer-modified electrodes. Biomaterials 33(30):7347–7355CrossRefGoogle Scholar
  15. 15.
    Liu Y, Yan J, Howland MC, Kwa T, Revzin A (2011) Micropatterned aptasensors for continuous monitoring of cytokine release from human leukocytes. Anal Chem 83(21):8286–8292, PMCID: 3235337CrossRefGoogle Scholar
  16. 16.
    Lee PP, Ramanathan M, Hunt CA, Garovoy MR (1996) An oligonucleotide blocks interferon-gamma signal transduction. Transplantation 62(9):1297–1301CrossRefGoogle Scholar
  17. 17.
    Balasubramanian V, Nguyen LT, Balasubramanian SV, Ramanathan M (1998) Interferon-gamma-inhibitory oligodeoxynucleotides alter the conformation of interferon-gamma. Mol Pharmacol 53(5):926–932Google Scholar
  18. 18.
    Tuleuova N, Jones CN, Yan J, Ramanculov E, Yokobayashi Y, Revzin A (2010) Development of an aptamer beacon for detection of interferon-gamma. Anal Chem 82(5):1851–1857CrossRefGoogle Scholar
  19. 19.
    Stoltenburg R, Reinemann C, Strehlitz B (2007) SELEX–a (r)evolutionary method to generate high-affinity nucleic acid ligands. Biomol Eng 24(4):381–403CrossRefGoogle Scholar
  20. 20.
    Wilson AB, McHugh SM, Deighton J, Ewan PW, Lachmann PJ (1993) A competitive inhibition ELISA for the quantification of human interferon-gamma. J Immunol Methods 162(2):247–255CrossRefGoogle Scholar
  21. 21.
    Acevedo B, Perera Y, Ruiz M, Rojas G, Benitez J, Ayala M et al (2002) Development and validation of a quantitative ELISA for the measurement of PSA concentration. Clin Chim Acta 317(1–2):55–63CrossRefGoogle Scholar
  22. 22.
    Vessella RL (1993) Trends in immunoassays of prostate-specific antigen: serum complexes and ultrasensitivity. Clin Chem 39(10):2035–2039Google Scholar
  23. 23.
    Matsumoto K, Konishi N, Hiasa Y, Kimura E, Takahashi Y, Shinohara K et al (1999) A highly sensitive enzyme-linked immunoassay for serum free prostate specific antigen (f-PSA). Clin Chim Acta 281(1–2):57–69CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.GlucoSentient, Inc.ChampaignUSA
  2. 2.Department of ChemistryTsinghua UniversityBeijingChina
  3. 3.Department of ChemistryUniversity of Illinois at Urbana-ChampaignUrbanaUSA

Personalised recommendations